Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study
The purpose of this study was to evaluate the impact of augmented prophylaxis (ciprofloxacin augmented with an aminoglycoside) compared with that of empirical prophylaxis (ciprofloxacin alone) on transrectal post-prostate biopsy infectious complication (PBIC) rates. A retrospective cohort study eval...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/12/1/56 |
| _version_ | 1797446952297693184 |
|---|---|
| author | Daniel J. G. Thirion Jean-Alexandre Caissy Florence Poulin Camille S. H. Lanfranchi Albin Deda Armen Aprikian Charles Frenette Sero Andonian |
| author_facet | Daniel J. G. Thirion Jean-Alexandre Caissy Florence Poulin Camille S. H. Lanfranchi Albin Deda Armen Aprikian Charles Frenette Sero Andonian |
| author_sort | Daniel J. G. Thirion |
| collection | DOAJ |
| description | The purpose of this study was to evaluate the impact of augmented prophylaxis (ciprofloxacin augmented with an aminoglycoside) compared with that of empirical prophylaxis (ciprofloxacin alone) on transrectal post-prostate biopsy infectious complication (PBIC) rates. A retrospective cohort study evaluated 2835 patients receiving either augmented or empirical prophylactic regimen before undergoing a transrectal ultrasound-guided prostate biopsy between January 2010 and October 2018. The patients were compared according to prophylactic regimen received. The incidence of PBICs and the impact of risk factors were evaluated. A total of 1849 patients received the empirical regimen, and 986 patients received the augmented regimen. The composite PBIC rate was 2.1% (<i>n</i> = 39) and 0.9% (<i>n</i> = 9) (<i>p</i> = 0.019), respectively, and the SIRS rate was 1.9% and 0.8% (<i>p</i> = 0.020), respectively. Of the 50 patients presenting with a PBIC, 29 (58%) had positive cultures (blood and/or urine) for <i>Escherichia coli</i>, of which 28 (97%) were ciprofloxacin-resistant. Taking a fluoroquinolone in the previous 6 months and having a previous urinary tract infection within 1 year prior to the biopsy had significant impact on PBIC rates (<i>p</i> = 0.009 and <i>p</i> = 0.011, respectively). Compared with ciprofloxacin alone, augmented prophylaxis was associated with significantly lower PBICs. |
| first_indexed | 2024-03-09T13:47:58Z |
| format | Article |
| id | doaj.art-391dbd5fa51c4743ab809eddac870da0 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-09T13:47:58Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-391dbd5fa51c4743ab809eddac870da02023-11-30T20:55:05ZengMDPI AGAntibiotics2079-63822022-12-011215610.3390/antibiotics12010056Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort StudyDaniel J. G. Thirion0Jean-Alexandre Caissy1Florence Poulin2Camille S. H. Lanfranchi3Albin Deda4Armen Aprikian5Charles Frenette6Sero Andonian7Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaFaculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, CanadaFaculty of Sciences, University of Geneva, 1211 Geneva, SwitzerlandFaculty of Sciences, University of Geneva, 1211 Geneva, SwitzerlandDepartment of Surgery, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaInfectious Diseases Department, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaUrology Department, Royal Victoria Hospital, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaThe purpose of this study was to evaluate the impact of augmented prophylaxis (ciprofloxacin augmented with an aminoglycoside) compared with that of empirical prophylaxis (ciprofloxacin alone) on transrectal post-prostate biopsy infectious complication (PBIC) rates. A retrospective cohort study evaluated 2835 patients receiving either augmented or empirical prophylactic regimen before undergoing a transrectal ultrasound-guided prostate biopsy between January 2010 and October 2018. The patients were compared according to prophylactic regimen received. The incidence of PBICs and the impact of risk factors were evaluated. A total of 1849 patients received the empirical regimen, and 986 patients received the augmented regimen. The composite PBIC rate was 2.1% (<i>n</i> = 39) and 0.9% (<i>n</i> = 9) (<i>p</i> = 0.019), respectively, and the SIRS rate was 1.9% and 0.8% (<i>p</i> = 0.020), respectively. Of the 50 patients presenting with a PBIC, 29 (58%) had positive cultures (blood and/or urine) for <i>Escherichia coli</i>, of which 28 (97%) were ciprofloxacin-resistant. Taking a fluoroquinolone in the previous 6 months and having a previous urinary tract infection within 1 year prior to the biopsy had significant impact on PBIC rates (<i>p</i> = 0.009 and <i>p</i> = 0.011, respectively). Compared with ciprofloxacin alone, augmented prophylaxis was associated with significantly lower PBICs.https://www.mdpi.com/2079-6382/12/1/56infection controlantimicrobial resistanceantibiotic prophylaxisaugmented prophylaxismultidrug resistancetargeted prophylaxis |
| spellingShingle | Daniel J. G. Thirion Jean-Alexandre Caissy Florence Poulin Camille S. H. Lanfranchi Albin Deda Armen Aprikian Charles Frenette Sero Andonian Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study Antibiotics infection control antimicrobial resistance antibiotic prophylaxis augmented prophylaxis multidrug resistance targeted prophylaxis |
| title | Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study |
| title_full | Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study |
| title_fullStr | Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study |
| title_full_unstemmed | Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study |
| title_short | Ciprofloxacin Alone vs. Ciprofloxacin plus an Aminoglycoside for the Prevention of Infectious Complications following a Transrectal Ultrasound-Guided Prostate Biopsy: A Retrospective Cohort Study |
| title_sort | ciprofloxacin alone vs ciprofloxacin plus an aminoglycoside for the prevention of infectious complications following a transrectal ultrasound guided prostate biopsy a retrospective cohort study |
| topic | infection control antimicrobial resistance antibiotic prophylaxis augmented prophylaxis multidrug resistance targeted prophylaxis |
| url | https://www.mdpi.com/2079-6382/12/1/56 |
| work_keys_str_mv | AT danieljgthirion ciprofloxacinalonevsciprofloxacinplusanaminoglycosideforthepreventionofinfectiouscomplicationsfollowingatransrectalultrasoundguidedprostatebiopsyaretrospectivecohortstudy AT jeanalexandrecaissy ciprofloxacinalonevsciprofloxacinplusanaminoglycosideforthepreventionofinfectiouscomplicationsfollowingatransrectalultrasoundguidedprostatebiopsyaretrospectivecohortstudy AT florencepoulin ciprofloxacinalonevsciprofloxacinplusanaminoglycosideforthepreventionofinfectiouscomplicationsfollowingatransrectalultrasoundguidedprostatebiopsyaretrospectivecohortstudy AT camilleshlanfranchi ciprofloxacinalonevsciprofloxacinplusanaminoglycosideforthepreventionofinfectiouscomplicationsfollowingatransrectalultrasoundguidedprostatebiopsyaretrospectivecohortstudy AT albindeda ciprofloxacinalonevsciprofloxacinplusanaminoglycosideforthepreventionofinfectiouscomplicationsfollowingatransrectalultrasoundguidedprostatebiopsyaretrospectivecohortstudy AT armenaprikian ciprofloxacinalonevsciprofloxacinplusanaminoglycosideforthepreventionofinfectiouscomplicationsfollowingatransrectalultrasoundguidedprostatebiopsyaretrospectivecohortstudy AT charlesfrenette ciprofloxacinalonevsciprofloxacinplusanaminoglycosideforthepreventionofinfectiouscomplicationsfollowingatransrectalultrasoundguidedprostatebiopsyaretrospectivecohortstudy AT seroandonian ciprofloxacinalonevsciprofloxacinplusanaminoglycosideforthepreventionofinfectiouscomplicationsfollowingatransrectalultrasoundguidedprostatebiopsyaretrospectivecohortstudy |